HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

CD66 antigens

Subscribe to New Research on CD66 antigens

granulocyte phosphoprotein; identifies a neutrophil-specific epitope within the hematopoietic system that is expressed by members of the carcinoembryonic antigen family of adhesion molecules; BGP - biliary glycoprotein; see also records for biliary glycoprotein 1 and 2

Also Known As:

C-CAM protein; C-CAM1; C-CAM2; CD66 antigen; CD66A antigen, human; CD66a antigen; CEA-related cell adhesion molecule 1; CEA-related cell adhesion molecule 1, rat; CEACAM1; CEACAM1 protein, human; CEACAM2; Ceacam1 protein, rat; biliary glycoprotein A; biliary glycoprotein I; carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein), human; cell-CAM 105; cellCAM 105; nonspecific cross-reacting antigen 160

Networked: 250 relevant articles (10 outcomes, 44 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Shively, John E: 22 articles (02/2015 - 01/2003)
2.	Najjar, Sonia M: 16 articles (11/2015 - 01/2002)
3.	Wagener, Christoph: 16 articles (12/2014 - 02/2002)
4.	Beauchemin, Nicole: 13 articles (01/2015 - 06/2006)
5.	Singer, Bernhard B: 12 articles (11/2015 - 06/2005)
6.	Blumberg, Richard S: 9 articles (01/2015 - 02/2002)
7.	Markel, Gal: 8 articles (03/2015 - 03/2004)
8.	Wagener, C: 8 articles (10/2011 - 02/2000)
9.	Schachter, Jacob: 7 articles (03/2015 - 11/2006)
10.	Schumacher, Udo: 7 articles (10/2012 - 05/2002)

Related Diseases

1.	Neoplasms (Cancer) 11/01/2015 - "Moreover, this inhibitory mechanism in many cases might hinder the efficacy of immunotherapeutic treatments of CEACAM1 malignancies because of tumor evasion by activated effector cells. " 01/01/2008 - "Alternative splicing of CEACAM1 generates 11 different splice variants, which include 1-4 ectodomains with either short or long cytoplasmic domain generated by the exclusion (CEACAM1-S) or inclusion (CEACAM1-L) of exon 7. Studies in rodents indicate that optimal ratios of CEACAM1 splice variants are required to inhibit colonic tumor cell growth. " 07/04/2007 - "Recently, however, several studies have shown that CEACAM1 actively contributes to malignant progression or migration in some types of tumor cells, suggesting that the role of CEACAM1 might be diverse among different types of cancer cells. " 10/05/1999 - "In this study, we determined the minimal domain of C-CAM1 that is required for its tumor-suppressive activity. " 09/30/1999 - "In this study, we define the subregions of the long cytoplasmic domain participating in the tumor inhibition phenotype of CEACAM1. "
2.	Neoplasm Metastasis (Metastasis) 02/18/2009 - "CEACAM1, L1, and HPA-binding site expression, all markers predicting metastasis in clinical studies, were preserved in the metastatic nodules. " 08/01/2014 - "The up-regulation of CEACAM1 expression may participate in tumorous angiogenesis, especially high expression of CEACAM1 promoted its capability of invasion and metastasis." 08/01/2014 - "High CEACAM1 expression and high MVD value were positively associated with lymph nodes metastasis and TNM stage, but negatively related to pathological grade (P<0.05). " 01/01/2014 - "CEACAM1 overexpression was also associated with lymph node metastasis (P=0.000) and higher clinical stage (P=0.001). " 02/14/2013 - "Chimeric immune cell profiling revealed diminished recruitment of CD11b(+)Gr1(+) myeloid-derived suppressor cells (MDSCs) to Ceacam1(-/-) metastatic livers and adoptive transfer of MDSCs confirmed the involvement of these immune cells in reduction of liver metastasis. "
3.	Prostatic Neoplasms (Prostate Cancer) 01/01/1999 - "Thus C-CAM1 recombinant adenovirus therapy may be a promising treatment for prostate cancer. " 05/01/2004 - "Our studies show that transcriptional repression by Sp2 represents one mechanism by which CEACAM1 tumor suppressor gene is down-regulated in prostate cancer." 01/01/2013 - "Since prostate cancer often involves loss of epithelial lumen formation, we hypothesized that CEACAM20 and CEACAM1 play important roles in lumen formation of normal prostate epithelium. " 09/01/2007 - "Strategies to either conserve the epithelial CEACAM1 or to target endothelial CEACAM1 might be useful for an antiangiogenic therapy of bladder and prostate cancer." 09/01/2007 - "Epithelial loss of cell adhesion molecule CEACAM1 activates angiogenesis in bladder and prostate cancer]."
4.	Colorectal Neoplasms (Colorectal Cancer) 09/15/2011 - "The aim of our study was to clarify the implication of CEACAM1 re-expression in colorectal cancer. " 09/15/2011 - "Re-expression of CEACAM1 is observed at the invasion front of colorectal cancer. " 09/15/2011 - "Invasion chamber and wound healing assays were performed for the effect of CEACAM1 expression on invasion and migration of colorectal cancer cells. " 09/15/2011 - "The reason why colorectal cancer cells re-expressed CEACAM1 remains unclear. " 09/15/2011 - "Recent reports have shown that CEACAM1 is overexpressed at protein level in colorectal cancer and correlated with clinical stage. "
5.	Breast Neoplasms (Breast Cancer) 10/01/2015 - "Taken together, our results demonstrate a systematic down-regulation of CEACAM1 in breast cancer and suggest that a strategy to restore CEACAM1 expression may be helpful for the treatment of breast cancer." 10/01/2015 - "The aim of this study was to investigate CEACAM1 expression in breast cancer in greater detail. " 10/23/2015 - "Serum concentrations of CEACAM1 may serve as a useful indicator for the presence of breast cancer." 10/23/2015 - "The optimal cut-off concentration of CEACAM1 was 475.82ng/ml for discriminating breast cancer from normal controls. " 10/23/2015 - "We investigated the serum concentrations of CEACAM1 in patients with breast cancer and determine the potential of serum CEACAM1 as a breast cancer biomarker. "

Related Drugs and Biologics

1.	Carbon Monoxide
2.	Carcinoembryonic Antigen
3.	Antigens
4.	Messenger RNA (mRNA)
5.	Cancer Vaccines
6.	Transferrin Receptors (Transferrin Receptor)
7.	Azoxymethane
8.	Antibodies
9.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
10.	Angiogenesis Inducing Agents (Angiogenesis Factor)

Related Therapies and Procedures

1.	Transplants (Transplant)
2.	Heterologous Transplantation (Xenotransplantation)
3.	Radiotherapy
4.	Ligation
5.	Immunotherapy